Genmab A/S to Post Q2 2024 Earnings of $0.28 Per Share, William Blair Forecasts (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB - Free Report) - Stock analysts at William Blair dropped their Q2 2024 EPS estimates for shares of Genmab A/S in a note issued to investors on Wednesday, April 3rd. William Blair analyst M. Phipps now expects that the company will post earnings of $0.28 per share for the quarter, down from their previous estimate of $0.33. The consensus estimate for Genmab A/S's current full-year earnings is $1.09 per share. William Blair also issued estimates for Genmab A/S's Q3 2024 earnings at $0.24 EPS, Q4 2024 earnings at $0.23 EPS and FY2024 earnings at $0.89 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, topping analysts' consensus estimates of $0.34 by $0.02. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. The firm had revenue of $675.29 million for the quarter, compared to analyst estimates of $678.14 million.

GMAB has been the subject of several other research reports. Citigroup downgraded shares of Genmab A/S from a "neutral" rating to a "sell" rating in a research report on Monday, January 22nd. Truist Financial restated a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Tuesday, March 26th. Morgan Stanley restated an "underweight" rating on shares of Genmab A/S in a research report on Tuesday, March 26th. HC Wainwright restated a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Thursday. Finally, BMO Capital Markets upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $48.50.

Genmab A/S Stock Up 0.4 %

Shares of GMAB traded up $0.11 during midday trading on Friday, hitting $29.76. The company had a trading volume of 237,451 shares, compared to its average volume of 626,695. The company's 50 day moving average price is $29.10 and its 200 day moving average price is $30.77. The stock has a market cap of $19.66 billion, a price-to-earnings ratio of 31.00, a PEG ratio of 1.37 and a beta of 0.99. Genmab A/S has a 52 week low of $26.32 and a 52 week high of $42.99.

Institutional Trading of Genmab A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. raised its holdings in shares of Genmab A/S by 1.7% during the first quarter. Rockefeller Capital Management L.P. now owns 18,508 shares of the company's stock valued at $698,000 after acquiring an additional 310 shares during the period. Ameriprise Financial Inc. increased its stake in Genmab A/S by 5.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 6,268 shares of the company's stock valued at $221,000 after buying an additional 337 shares during the period. Geode Capital Management LLC increased its stake in Genmab A/S by 1.0% in the 2nd quarter. Geode Capital Management LLC now owns 41,715 shares of the company's stock valued at $1,586,000 after buying an additional 408 shares during the period. HBK Sorce Advisory LLC increased its stake in Genmab A/S by 4.8% in the 3rd quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company's stock valued at $322,000 after buying an additional 419 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in Genmab A/S by 86.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company's stock valued at $38,000 after buying an additional 498 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.